Narrative review explores repurposing approved non-antibiotic pharmaceuticals against multidrug-resistant pathogens, highlighting a viable alternative to novel antibiotic discovery.
Antimicrobial resistance (AMR) is one of the most serious threats to global public health, undermining decades of progress in the treatment of infectious diseases. The rapid emergence of multidrug-resistant pathogens, particularly in hospital-associated infections, has outpaced the development of new antibiotics with unique chemical structures. Thus, the need for alternative strategies that do not solely rely on discovering novel compounds is required. But is this possible? One such approach is the use of non-antibiotic drugs, in which agents originally developed for unrelated clinical purposes are repurposed to enhance the activity of existing antibiotics.
No takes yet. Share an insight, caveat, or question.
Arya Gupta (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: